Streptomyces tsukubaensis

A fermentation broth of Streptomyces tsukubaensis No. 9993 is filtered and the mycelial cake is extracted with acetone. The filtrate is combined with the acetone extract and passed through a column of Diaion HP-20. The dilution with 75 % aqueous acetone, by evaporation gives an oily residue that is extracted with ethyl acetate and submitted to column chromatography over silica gel. 

Pharmacology Tacrolimus is a macrolide immunosuppressant produced by Streptomyces tsukubaensis. The mechanism of action of tacrolimus in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. Pharmacokinetics ... 

Tacrolimus (previously known as FK506) is a macrolide antibiotic which is obtained from the fungus Streptomyces tsukubaensis. Tacrolimus binds in-tracellularly to the protein FKBP (FK binding protein) which is distinct from the protein that binds cyclosporine. However both drug-protein complexes associate in a similar way with calcineurin and inhibits its serine/threonine phosphatase activity, although the immunosuppressive potency of tacrolimus is approximately 100 fold higher than that of cyclosporine. 

It is an immunosuppressant macrolide antibiotic produced by Streptomyces tsukubaensis. Like cyclosporine, tacrolimus binds to a cytoplasmic immunophylin and the complex inhibits the activity of the calcium dependent phosphatase known as calcineurin. This in turn, inhibits the translocation of the transcription factor NF-AT into the cell nucleus, blocking the initiation of NF-AT dependent T-cell responses. It is indicated in atopic dermatitis. 

Tacrolimus (FK 506) is an immunosuppressant macrolide antibiotic produced by Streptomyces tsukubaensis. It is not chemically related to cyclosporine, but their mechanisms of action are similar. Both drugs bind to cytoplasmic peptidyl-prolyl isomerases that are abundant in all tissues. While cyclosporine binds to cyclophilin, tacrolimus binds to the immunophilin FK-binding protein (FKBP). Both complexes inhibit calcineurin, which is necessary for the activation of the T-cell-specific transcription factor NF-AT. 

Tacrolimus is a 23-membered lactone chain isolated in 1984 from Streptomyces tsukubaensis, although it was originally found in a soil fungus. It is a macrolide antibiotic, and its name is derived from Tsukuba macrolide immunosuppressant. ... 

An unusual and clinically significant macrolide isolated from Streptomyces tsukubaensis is FK-506 (tacrolimus) (Figure 3.69), which contains a... 

The novel 17-allyl-l,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-l-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-ll,28-dioxa-4-azatrcyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone (FR-900506), substance can be produced by culturing a FR-900506 substance(s)-producing strain belonging to the genus Streptomyces (e.g. Streptomyces tsukubaensis No. 9993, FERM BP-927) in a nutrient medium. 

A culture medium (160 ml) containing glycerin (1%), corn starch (1%), glucose (0.5%), cottonseed meal (1%), dried yeast (0.5%), corn steep liquor (0.5%) and calcium carbonate (0.2%) (adjusted to pH 6.5) was poured into each often 500 ml-Erlenmeyer flasks and sterilized at 120°C for 30 min. A loopful of slant culture of Streptomyces tsukubaensis No. 9993 was inoculated to each of the medium and cultured at 30°C for 4 days on a rotary shaker. 

Tacrolimus is a macrolide antibiotic from Streptomyces tsukubaensis. In principle, it acts like ciclosporin. At the molecular level, however, its receptor is not cyclophilin but a so-called FK-binding protein. Tacrolimus is likewise used to prevent allograft rejection. Its epithelial penetrability is superior to that of ciclosporin, allowing topical application in atopic dermatitis. 

FK506 is the propriety name given to an immunosuppressant by a Japanese company. FK506 is a macrolide antibiotic, isolated from streptomyces tsukubaensis. It is a potent inhibitor of T cell activation, preventing allograft rejection. FK506 binds to FK-binding proteins, the FKBP s. 

Tacrolimus is a macrolide antibiotic produced by the soil fungus Streptomyces tsukubaensis. It is one hundred times more potent than cyclosporine in vitro, but is equally as toxic if not more so. It suppresses both humoral and cell-media ted immune responses. Although chemically distinct from cyclosporine it elicits similar immunosuppressant effects. 

Also see color figure.) Structures for the immunosuppressant, FK506 (tacrolimus). Tacrolimus is a macrolide isolated from Streptomyces tsukubaensis. Shown from left to right in approximately the same orientation are the simple line structure, a stick- structure, and a space-filling structure. The stick and space-filling structures are based on the 3-dimensional structure of the molecule bound to the immunophilin FKBP. Protein data bank designation IFKF. 

Discovery and Biochemical Studies FK506 was isolated in the course of the search for immunosuppressant from Streptomyces tsukubaensis [1,2]. The structure was determined as shown in 1 [3]. FK506 inhibited mixed lymphocyte reaction, cytotoxic T-cell generation, and expression of early T-cell activation genes [2,4]. 

FK506 (tacrolimus) (23) is a 23-membered macrocyclic lactone isolated from Streptomyces tsukubaensis and is structurally related to rapamycin. It displays antifungal and immunosuppressive activities. It is marketed as an immunosuppressant that can be used in transplant therapy and several autoimmune disorders. Rapamycin and FK506 share the same common cellular receptor FKBP, but they present a different mechanism of action. Similar to cyclosporine A, FK506 suppresses T-cell activation at the level of lymphokine production and prevents the expression of the interleukin 2 receptor (IL-2R). ... 

Tacrolimus (Prograf, FK506) is a macrolide antibiotic produced by Streptomyces tsukubaensis. 

The fungal-derived cyclic peptide cyclosporine (cyclosporin A) was found some years ago to be an immunosuppressive agent in organ and tissue transplant surgery. Another compound with this same type of use and that also acts by the inhibition of T-cell activation is the macrolide tacrolimus (FK-506), from Streptomyces tsukubaensis (2). 

C44H69NO12, Mr 804.04, prisms, mp. 127-129°C, [ajj, -84.4° (CHCI3), a macrolactam lactone produced by Streptomyces tsukubaensis, in which a long-chain hy-droxycarboxylic acid is cyclized with L- pipecoUc acid as bridging unit. FK-506 is structurally related to rapamycin and has been prepared synthetically. It exhibits immunosuppressive activity by suppression of cell-mediated and humoral immune responses. It has been available in Japan since 1993, in Europe and USA since 1996 under the name Prograf tacrolimus) for use in transplantation medicine to suppress rejection reactions. FK-506 is also effective in the treatment of autoimmune diseases, e. g., multiple sclerosis, psoriasis, or rheumatoid arthritis. 

They have been identified from Streptomyces tsukubaensis and S. hygroscopicus and are reported as immunosuppressants with higher potency than cyclosporin A. 

---